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Edited by Michael R. BubbAbstract Platelet-activating factor (PAF) augments angiogen-
esis by promoting the synthesis of a variety of angiogenic factors,
via the nuclear factor (NF)-jB activation. Recently, we reported
that PAF upregulates MMP-9 expression in a NF-jB-dependent
manner. In this study, we investigated the signaling pathway in-
volved in PAF-induced MMP-9 expression in ECV304 cells.
Our current data indicate that the Ca2+- or phosphatidylinositol
3-kinase (PI3K)-dependent signaling pathway is necessary for
PAF-induced MMP-9 expression. Furthermore, PAF-induced
NF-jB activation was blocked by selective inhibitors of Ca2+,
PI3K, or extracellular signal-regulated kinase (ERK). Our
results suggest that PAF-induced MMP-9 expression, in a
NF-jB-dependent manner, is regulated by Ca2+, PI3K and
ERK signaling pathways.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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factor-jB1. Introduction
Angiogenesis, the formation of new blood vessels from exit-
ing vasculature is a tightly regulated event playing an impor-
tant role in development, wound healing and pathological
conditions such as tumor growth and survival. The degrada-
tion of tissue barriers in the extracellular matrix (ECM), par-
ticularly the basement membrane, is an essential step for
sprouting endothelial cells to invade the surrounding intersti-
tial matrix and to initiate angiogenesis. Among the enzymes in-
volved in this degradation, matrix metalloproteinases (MMPs)
secreted by endothelial cells are hypothesized to play a key role
in the processes of matrix remodeling and endothelial cell
migration during angiogenesis [1,2]. MMPs are a family of se-
creted and membrane-associated zinc-dependent extracellular
endopeptidases, capable of degrading essential ECM compo-
nents. Among MMPs, MMP-9, capable of degrading nativeAbbreviations: MMP, matrix metalloproteinase; PAF, platelet-activat-
ing factor; PI3K, phosphatidylinositol 3-kinase; ERK, extracellular
signal-regulated kinase; MAPK, mitogen-activating protein kinase
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nents of the ECM, appears to play an important role in cell
migration and invasion [3,4]. Recent reports have shown that
MMP-9 deﬁciency decreases inﬂammatory cell invasion and
capillary formation in vivo by impairing collagen organization
and angiogenesis [5]. While the expression of MMP-9 is often
observed in a variety of cancer cells, stimulation of cells with
growth factors and cytokines including platelet-activating fac-
tor (PAF) can also induce MMP-9 expression [6–13].
PAF, which is produced by a variety of inﬂammatory cells,
is an important mediator involved in cellular activation, fertil-
ization, intracellular signaling, apoptosis and a myriad of path-
ological conditions such as septic shock, hematological
abnormalities, tumor growth and metastasis [14–18]. We have
previously demonstrated that PAF is a proximal inducer of the
transcription factor, nuclear factor (NF)-jB, a key component
necessary for the expression of many proinﬂammatory cyto-
kines and immunoregulatory molecules [19,20] in response to
inﬂammatory stimuli [21,22] and microbial infection [23].
PAF augments angiogenesis by promoting a variety of angio-
genic factors via activation of NF-jB [24]. PAF mediates its
activity by the activation of a speciﬁc G-protein-coupled, se-
ven-transmembrane receptor, the PAF-receptor, leading to
hydrolysis of phosphatidylcholine, release of calcium from
endoplasmic reticulum stores and activation of protein kinase
C (PKC), phospholipase C, phospholipase A2, phosphatidylin-
ositol 3-kinase (PI3K) and the mitogen-activated protein ki-
nase (MAPK) cascade [25–29]. However, their biological
roles in PAF signaling remain to be determined and the discov-
ery of important signaling molecules for PAF would serve as
potential targets for anti-angiogenic therapy.
Several reports have demonstrated that the signaling re-
quired for MMP-9 production might diﬀer, in part, depending
on the types of cell lines and stimulants. Production of MMP-9
by EGF requires the activation of Erk, p38 and PI3K signaling
in an ovarian cancer cell line, OVCA 429 [30]. Production of
MMP-9 by IL-1b is dependent on the activation of Erk and
Akt but not p38 in a ﬁbroblast cell line, Balb 3T3 [31]; whereas
in a breast cancer cell line, SKBr3, this is Erk-dependent but
PI3K-independent [32,33]. Recently, it has been demonstrated
that PAF-induced chemokine gene expression requires NF-jB
activation and Ca2+/calcineurin signaling pathways [34]. NF-
jB activity has been reported to be associated with expression
of MMP-9 [35,36] and NF-jB-dependent MMP-9 is known to
play a role in PAF-induced angiogenesis [13]. Although
PAF-induced MMP-9 production appears to be dependentblished by Elsevier B.V. All rights reserved.
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naling pathway that induces MMP-9 expression remains lar-
gely unclear. In this study, we showed that signaling
pathways, Ca2+, PI3K and ERK were involved in PAF-
induced MMP-9 expression in ECV304 cells.2. Materials and methods
2.1. Reagents
PAF (1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) was pur-
chased from Sigma Chemical Co. (St. Louis, MO). The PAF receptor
antagonist, WEB2170, was a gift from Dr. C.K. Rhee (College of Med-
icine, Dankook University, Korea). Parthenolide, BAPTA-AM,
PD98059 and SB203580 were purchased from BIOMOL Research
Laboratories Inc. (Plymouth Meeting, PA, USA), whereas wortman-
nin was from Calbiochem (La Jolla, CA). p38 MAPK assay kit and
antibodies against phospho-Akt (p-Akt), Akt, phospho-ERK (p-
ERK), ERK, phospho-p38 (p-p38) and p38 were purchased from Cell
Signaling (Beverly, MA, USA). Antibody against IjBa was from Santa
Cruz Biotechology Inc. (Santa Cruz, CA).
2.2. Cell culture
ECV304 cells, an immortalized and transformed human vascular
endothelial cell line [37] was maintained in Dulbeccos modiﬁed Ea-
gle medium (DMEM, GIBCO, Island, NY) supplemented with 10%
(v/v) fetal bovine serum (CAMBREX Co., Walkersville, MD) at
37 C in a 5% CO2 atmosphere. We have already demonstrated that
ECV304 cell line is of endothelial origin using immunohistochemis-
try [13].
2.3. Measurement of [Ca2+]i
Cells were grown on poly-L-lysine-coated glass coverslips for 12 h
prior to experiment, then incubated in a physiological solution
(138 mM NaCl, 6 mM KCl, 1 mM MgSO4, 1 mM Na2HPO4, 5 mM
glucose, 10 mM HEPES and 0.1% BSA) with 5 lM Fura-2/AM
(Molecular Probe, Eugene, OR, USA) at 25 C for 45 min. The cells
were washed twice with the dye-free physiological solution and
mounted in an acrylamide chamber that allows perfusion of incubation
medium. Fura-2/AM ﬂuorescence was measured at excitation wave-
lengths 340 and 380 nm and at an emission wavelength 510 nm using
an Olympus-IX70 ﬂuorescence microscope coupled to a digital Cool
CCD camera (CoolSNAP fx CCD Camera, Roper Scientiﬁc, Tucson,
AZ, USA). All calcium data were analyzed by MetaFlour (version 5,
MetaFlour, West Chester, PA, USA).
2.4. Western blotting analysis
Cell lysates were prepared in radioimmunoprecipitation assay buﬀer
(0.1% SDS, 1% IGEPAL, 0.5% sodium deoxycholate and 1 mM phen-
ylmethylsulfonyl ﬂuoride), and equal amounts of the lysates were sep-
arated on 10% SDS–polyacrylamide gel under reducing conditions and
then transferred onto Protran nitrocellulose membranes (Schleicher &
Schuell, NH). Equal protein loading was veriﬁed by both staining the
gel and the membrane with Coomassie brilliant blue R-250 and Pon-
ceau S (Sigma), respectively. Membranes were blocked for 1 h at room
temperature in 5% skim milk in TBS followed by 1 h incubation with
primary antibody. Blots were washed for 15 min with three changes of
TBS-0.05% Tween 20 solution followed by 1 h incubation at room
temperature with the HRP-conjugated anti-rabbit IgG antibody (San-
ta Cruz Biotechnology Inc). Blots were washed again for 15 min and
ﬁnally developed in the ECL Western detection reagents (Amer-
sham-Pharmacia Biotech, Piscataway, NJ, USA).
2.5. Real-time RT-PCR
RNAwas prepared as previously described [21,22]. Reverse transcrip-
tionwas performedusing 0.1 lg of totalRNA in a 10 ll reactionmixture
(Promega, Madison, WI), containing oligo(dT) and avian myeloblasto-
sis virus reverse transcriptase. PCR was performed on the Roter-Gene
3000 System (Corbett Research, Morklake, Australia) using the SYBR
Green PCR Master Mix Reagent Kit (Qiagen, Valencia, CA). The
primers used are as follows:MMP-9 for real-time PCR, 5 0-TGACAGC-GACAAGAAGTG-3 0 and 5 0-CAGTGAAGCGGTACATAGG-3 0;
MMP-9 for the visualization of the results, 5 0-ATCCAGTTT
GGTGTCGCGGAGC-30 and 5 0-GAAGGGGAAGACGCACAG-
CT-3 0; b-actin, 5 0-CTGAAGTCACCCATTGAACATGGC-3 0 and 5 0-
CAGAGCAGTAATCTCCTTCTGCAT-3 0. The relative levels of
mRNA of MMP-9 were calculated using the standard curve generated
from cDNA dilutions. The mean cycle threshold (Ct) values from qua-
druplicatemeasurementswereused to calculate the gene expression,with
normalization to b-actin as an internal control. Calculations of the rela-
tive level of gene expression were conducted according to the comple-
mentary computer software (Corbett Research) using a standard
curve. cDNA, ampliﬁed by PCR (Perkin Elmer System 2400, Norwalk,
CT), was visualized after staining with ethidium bromide.
2.6. Zymography
Cells (1 · 106/60 mm dish) were seeded in complete medium and
cultured for 6 h to anchor the cells. The cells were washed with ser-
um-free medium twice and grown in serum-free medium overnight,
then treated with PAF (2 lM) for 24 h. The supernatant was col-
lected to assess gelatinase activity and concentrated 30-fold using
an Amicon Centricon (Millipore Co., Bedford, MA, USA). The
samples were electrophoretically separated onto 8.5% SDS–poly-
acrylamide gel containing 1 mg/ml of gelatin (Sigma). After electro-
phoresis, the gel was washed at room temperature for 1 h in wash
buﬀer (50 mM Tris-Cl, pH 7.4 and 2.5% Triton X-100) and incu-
bated at 37 C overnight in incubation buﬀer (50 mM Tris–Cl, pH
7.4, 75 mM NaCl and 2.5 mM CaCl2). The gel was stained with
0.2% Coomassie brilliant blue R-250 (Sigma) in a mixture of meth-
anol:acetic acid:water (2:1:7) for 2 h and then destained in the same
solution, without dye. Clear zones against the blue background indi-
cated the presence of gelatinolytic activity.
2.7. Luciferase reporter assay
TheHindIII–KpnI fragment comprising1285 to 20 bp of theMMP-
9 promoter (pGL3-M9Pwt, a kind gift from Dr. S.-T. Lee, Yonsei
University, Korea) was cloned upstream of the promoterless luciferase
reporter vector in the pGL3-Basic. Plasmid DNA was prepared using
commercial kits (QIAGEN, Chatsworth, CA). ECV304 cells were cul-
tured to 60–80% conﬂuence in 24-well plates. Next, 0.2 lg of plasmid
DNA and 1 ll of LipofectAMINE reagent (Life Technologies, Inc.,
Gaithersburg, MD) were separately diluted in 50 ll of Opti-MEM re-
duced serum medium (Life Technologies, Inc.), mixed together and
incubated at room temperature for 1 h. Plates were then washed with
serum-free medium, 200 ll of Opti-MEM reduced serum medium was
added and the diluted solution was added to the cells. Plates were then
incubated at 37 C for 8 h, after which time growth medium containing
10% serum was added and cells were maintained for an additional 16 h.
Cells were then either left untreated, or were treated with 2 lM of PAF
for 8 h. Cell extracts were prepared using passive lysis buﬀer (Promega,
Madison, WI). Luciferase assays were carried out using the Lumat
LB9501 luminometer (Berthold, Germany). All experiments were re-
peated at least three times, with two diﬀerent batches of puriﬁed DNA.
2.8. Electrophoretic mobility shift assay
Nuclear extracts were prepared from the cells, as previously de-
scribed [21,22]. To inhibit endogenous protease activity, 1 mM phenyl-
methylsulfonyl ﬂuoride was added. As a probe for the gel retardation
assay, an oligonucleotide containing the Igj-chain binding site (jB, 5 0-
CCGGTTAACAGAGGGGGCTTTCCGAG-3 0) was synthesized.
The two complementary strands were annealed and labeled with
[a-32P]dCTP. Labeled oligonucleotides (10000 cpm), 12 lg of nuclear
extracts and binding buﬀer [10 mM Tris–HCl, pH 7.6, 500 mM KCl,
10 mM EDTA, 50% glycerol, 100 ng of poly(dIdC) and 1 mM DTT]
were incubated for 30 min at room temperature in a ﬁnal volume of
20 ll. The reaction mixture was analyzed by electrophoresis on a 5%
polyacrylamide gel in 0.5 · Tris-borate buﬀer. Speciﬁc binding was
controlled by competition with a 50-fold excess of cold jB or cAMP
response element (CRE) oligonucleotide.
2.9. Statistical analysis
Data are represented as the mean ± S.E. Statistical signiﬁcance was
determined by the Students t-test when two data sets were analyzed or,
alternatively, by ANOVA followed by the appropriate post-hoc test
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4.5). All experiments were conducted two or more times. Reproducible
results were obtained and representative data are, therefore, shown in
the ﬁgures.Fig. 1. Eﬀect of PAF on the rise in [Ca2+]i and the phosphorylation of
Akt , ERK and p38. (A) For the detection of change in intracellular
Ca2+ concentration, Fura-2/AM-preloaded ECV304 cells (1 · 106)
were treated with 2 lM of PAF. Fura-2/AM 340/380 nm ratio of an
individual cell was examined. For detection of PI3K activity (B),
phosphorylated ERK (C) and p38 (D), cell lysates were probed with
anti-p-Akt, anti-p-ERK and anti-p-p38 antibodies as described in
Section 2. Values are expressed as means ± S.E.3. Results
3.1. PAF increases intracellular Ca2+ level, and phosphorylation
of PI3K and ERK, leading to MMP-9 expression
Recently, we have shown that PAF induced MMP-9 expres-
sion as a result of NF-jB activation in ECV304 cells [13]. To
elucidate the involvement of Ca2+, PI3K, ERK and p38 signal-
ing in PAF-induced MMP-9 expression, we determined the
levels of Ca2+, phosphorylated PI3K, ERK and p38 after
PAF treatment. As shown in Fig. 1A, the rise in [Ca2+]i after
PAF stimulation peaked within 1 min and then decreased.Wes-
tern blot analysis using phospho-speciﬁc antibodies directed
against Akt, ERK and p38 showed that PAF rapidly activated
Akt (Fig. 1B), ERK (Fig. 1C) and p38 (Fig. 1D). The phos-
phorylated Akt level peaked at 1 min and phosphorylated
ERK and p38 levels were maximal at 5 min of PAF exposure.
The use of non-phospho antibodies did not detect changes in
the expression of these signal molecules during this short treat-
ment period with PAF (Fig. 1B and C). Next, we determined
the roles of Ca2+ and PI3K in PAF-induced MMP-9 expression
by the use of selective inhibitors. Pretreatment of cells with an
inhibitor of Ca2+ or PI3K resulted in a signiﬁcant inhibition of
PAF-induced MMP-9 gelatinolytic activity (Fig. 2A), mRNA
expression (Fig. 2B), and promoter activity (Fig. 2C) in a
dose-dependent manner. To determine the role of MAPK in
PAF-induced MMP-9 expression, we examined the eﬀect of
selective inhibitor of ERK or p38. The inhibitor of ERK,
PD98059, inhibited PAF-induced MMP-9 gelatinolytic activity
(Fig. 3A), mRNA expression (Fig. 3B) and promoter activity
(Fig. 3C). By contrast, PAF-induced MMP-9 expression was
augmented by SB203580 (Fig. 3) which inhibited p38-induced
phosphorylation of ATF-2 at Thr71 (data not shown). These
data suggest that Ca2+, PI3K and ERK, but not p38, serve as
positive regulators of PAF-induced MMP-9 expression.
3.2. The dual, Ca2+- or PI3K-dependent, signaling pathways are
required for PAF-induced MMP-9 expression
The cross-talk of PAF-induced Ca2+, PI3K and ERK signal-
ing was examined. PAF-induced rise of [Ca2+]i was inhibited
by the PAF antagonist, but not by the PI3K inhibitor
(Fig. 4A). PAF-induced activation of Akt was inhibited by
the PAF antagonist or PI3K inhibitor, but not by the Ca2+
inhibitor (Fig. 4B). PAF-induced activation of ERK was sig-
niﬁcantly inhibited by the PAF antagonist and partially inhib-
ited by the Ca2+ or PI3K inhibitor (Fig. 4C). These results
indicate that PAF activates ERK through Ca2+- or PI3K-
dependent pathway, which is mutually independent. We next
examined the MMP-9 expression by the use of the two inhib-
itors, BAPTA-AM and wortmannin, in combination. PAF-in-
duced MMP-9 gelatinolytic activity (Fig. 5A), mRNA
expression (Fig. 5B) and promoter activity (Fig. 5C) were
completely inhibited by the suboptimal concentrations of the
two inhibitors. These data suggest that dual signaling path-
ways, Ca2+- or PI3K-dependent, are critical and suﬃcient for
PAF-induced MMP-9 expression and the ERK is partially in-
volved in the PAF-induced dual pathways.3.3. Ca2+, PI3K and ERK are involved in PAF-induced NF-jB
activation
Given that PAF induces MMP-9 expression in a NF-jB-
dependent manner [13], we hypothesized that Ca2+, PI3K and
ERK might be involved in PAF-induced NF-jB activation,
leading to MMP-9 expression. The eﬀects of selective inhibitors
of Ca2+, PI3K and ERK on the PAF-induced NF-jB activa-
tion were examined. As shown in Fig. 6A, addition of PAF into
the cells resulted in the activation of NF-jB, an eﬀect which was
Fig. 2. Eﬀect of Ca2+ and PI3K on PAF-induced MMP-9 expression.
ECV304 cells (1 · 106) were treated with BAPTA-AM (BAP) or
wortmannin (Wor) 20 min prior to 2 lM of PAF treatment. (A) For
detection of gelatinolytic activity of MMP-9, zymography was
performed. Conditioned media were collected after 24 h and aliquots
corresponding to equal amounts of cells were subjected to gelatin
zymography. The positions of MMP-9 and MMP-2 are indicated. (B)
Real-time RT-PCR was performed, as described in Section 2. The
results of agarose gel electrophoresis of RT-PCR are shown (inset), as
are the combined quantitative analysis results by real-time RT-PCR.
(C) MMP-9 promoter activity was assayed, as described in Section 2.
Luciferase activity was normalized by b-galactosidase activity, in order
to determine transfection eﬃciency. All promoter activities are shown
as fold activation relative to control. *P < 0.001 compared with control
group; #P < 0.001 compared with PAF-treated group. Values are
expressed as means ± S.E.
Fig. 3. Eﬀect of ERK and p38 on PAF-induced MMP-9 expression.
ECV304 cells (1 · 106) were treated with PD98059 (PD) or SB203580
(SB) 20 min prior to 2 lM of PAF treatment. Zymography (A), real-
time RT-PCR (B), and luciferase reporter assay (C) were performed, as
described in Fig. 2. *P < 0.001 compared with control group;
#P < 0.001 compared with PAF-treated group. Values are expressed
as means ± S.E.
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PD98059 but not by SB203580. To determine if inhibition of
PAF-induced NF-jB activation is the consequence of upstream
inhibition or a direct eﬀect on DNA binding, we performedanalysis of IjBa degradation in the presence of PAF and signal-
ing inhibitors. IjBa degradation by PAF was blocked by BAP-
TA-AM, wortmannin and PD98059 but not by SB203580
(Fig. 6B). Therefore, these data suggest that PAF increases
MMP-9 expression through NF-jB activation, which resulted
from Ca2+- or PI3K-dependent signaling pathway.4. Discussion
PAF is one of the most potent phospholipids that transmit
outside-in signals to the intracellular transduction systems in
Fig. 4. Eﬀect of inhibitors on PAF-increased the level of [Ca2+]i,
phosphorylated Akt and ERK. ECV304 cells (1 · 106) were treated
with WEB2170 (WEB), PD98059 (PD), wortmannin (Wor), or
BAPTA-AM (BAP) 20 min prior to PAF treatment (2 lM). Intracel-
lular Ca2+ concentration was detected at the indicated times (A) and
cell lysates were probed with anti-p-Akt (B) and anti-p-ERK (C) as
described in Fig. 1. Values are expressed as means ± S.E.
Fig. 5. Eﬀect of Ca2+ and PI3K in combination on PAF-induced
MMP-9 expression. ECV304 cells (1 · 106) were treated with wort-
mannin (Wor) and BAPTA-AM (BAP) 20 min prior to PAF
treatment. Zymography (A), real-time RT-PCR (B) and luciferase
reporter assay (C) were performed, as described in Fig. 2. *P < 0.001
compared with control group; #P < 0.001 compared with PAF-treated
group; §P<0.01 compared with PAF plus BAPTA-AM-treated group.
Values are expressed as means ± S.E.
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inﬂammatory and immune responses as well as in vascular
functions [16–18,38]. Previous studies from our laboratory
have demonstrated that PAF has an ability to enhance tumor
metastasis [18] and promote angiogenesis through the activa-
tion of NF-jB [24]. Recently, we demonstrated that PAF in-
creases mRNA expression, protein synthesis and activity of
MMP-9 in ECV304 cells via the activation of NF-jB and that
MMP-9 produced by the PAF is an important eﬀector mole-
cule in PAF-induced angiogenesis [13].
The intracellular actions of PAF are mediated through the
PAF receptor that is expressed on the surface of a variety of
cell types and interacts with multiple G proteins, resulting inthe simultaneous activation of distinct signaling pathways. In
the present study, we determined the involvement of Ca2+,
PI3K and ERK in PAF-mediated signaling to NF-jB. The
major novel results of this study are that: (1) Ca2+, PI3K
and ERK played a role in the regulation of PAF-induced
MMP-9 expression and activity (Figs. 1–3), (2) both Ca2+
and PI3K, acting upstream of ERK, were required for PAF
signaling to express MMP-9 (Fig. 5) and (3) ERK activated
by Ca2+ or PI3K was partially involved in PAF-induced NF-
jB activation (Fig. 6).
MMP-9 is proposed to play a critical role in tumor cell
invasion, metastasis and angiogenesis. Recent studies have
demonstrated that MMP-9 expression by a stimulus is depen-
dent on the integration of speciﬁc signal transduction path-
Fig. 6. Eﬀect of inhibitors on PAF-induced NF-jB activation.
ECV304 cells (1 · 106) were treated with inhibitors, BAPTA-AM
(BAP), wortmannin (Wor), PD98059 (PD) and SB203580 (SB) 20 min
prior to PAF treatment. (A) Nuclear extracts were prepared 1 h after
PAF treatment, incubated with a-32P-labeled jB or CRE oligonucleo-
tide, and electrophoresed on a 5% polyacrylamide gel. (B) Cell extracts
were prepared 30 min after PAF treatment, probed with anti-IjBa
antibody.
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activation of the MMP-9 gene [39–42]. Recently, it has been
shown that Ca2+ induces MMP-9 expression in oral keratino-
cytes and carcinoma, and is involved in the activation and
truncation of proMMP-9 [43,44]. The role of PKC, MAPK
and PI3K-dependent signaling in the regulation of MMP-9
expression are not consistent in various cell types [32,33,45–
47]. In this study, we have shown that PAF activated both
Ca2+ and PI3K pathways, leading to the activation of ERK
in ECV304 cells (Fig. 4). Both Ca2+ and PI3K inhibitors
blocked PAF-induced MMP-9 expression signiﬁcantly (Figs.
2 and 3). With the use of two inhibitors in combination,
PAF-induced MMP-9 expression was blocked completely
(Fig. 5), suggesting that dual signaling pathways, Ca2+- or
PI3K-dependent, are critical and suﬃcient for PAF-induced
MMP-9 expression. Moreover, we have shown that the ERK
inhibitor blocked PAF-induced MMP-9 expression, but the
p38 inhibitor enhanced PAF-induced MMP-9 expression
(Fig. 3). These ﬁndings are consistent with the report that
Ca2+ induces MMP-9 expression by reciprocal regulation be-
tween the ERK and p38 MAPK pathways [44]. Furthermore,
we showed here that PAF-induced ERK activation was par-
tially blocked by Ca2+ and PI3K inhibitors (Fig. 4) and
PAF-induced NF-jB activation was signiﬁcantly but not com-pletely blocked by the ERK inhibitor (Fig. 6), suggesting that
MMP-9 transcriptional activation may require the cooperation
of ERK and other signaling molecules and transcriptional fac-
tors activated by Ca2+- and PI3K-dependent signaling path-
ways. Additional studies are required to determine the other
signaling pathways leading to NF-jB activation and transcrip-
tional factors such as AP-1 and Ets.
Another interesting ﬁnding of this study from zymograms
in Figs. 2, 3 and 5 is that in addition to inducing MMP-9
secretion, PAF also induced MMP-2 secretion, which was
signiﬁcantly inhibited by BAPTA-AM, PD98059 and
SB203580 but not by wortmannin. Given that inhibition of
NF-jB failed to inhibit PAF-induced MMP-2 secretion
(unpublished our data), these data suggest that MMP-2
and 9 secretions by PAF in ECV304 cells are regulated
by diﬀerent mechanisms.
It has been reported thatMMP-9 signaling is cell-type speciﬁc
[39–47]. We have used human vascular endothelial ECV304
cells which have undergone spontaneous transformation and
immortalization in this study. Therefore, the signaling pathway
to MMP-9 expression in ECV304 cells may be diﬀerent from
that of primary human vascular endothelial cells. However,
we could not elucidate the MMP-9 signaling pathway induced
by PAF in HUVECs, because MMP-9 expression did not occur
in PAF-stimulated HUVECs. Similar ﬁnding that PAF induces
activation of MMP-2 but not the expression of MMP-9 in HU-
VECs has been reported by other investigators [48].
Augmented expression of MMPs is characteristic of a group
of chronic inﬂammatory disorders. Our ﬁnding that PAF-in-
duced MMP-9 expression in a NF-jB-dependent manner
and is regulated by Ca2+, PI3K and ERK has broadened our
knowledge on the regulation of this important protease in-
volved in multiple pathophysiological conditions like tumor
invasion and metastasis. Therefore, this study may be impor-
tant for the development of new therapeutic agents for the pre-
vention of excessive matrix degradation and remodeling during
chronic inﬂammatory diseases and tumors.
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